CN120732855A - 用于治疗疾病的法尼醇x受体激动剂 - Google Patents

用于治疗疾病的法尼醇x受体激动剂

Info

Publication number
CN120732855A
CN120732855A CN202511190792.8A CN202511190792A CN120732855A CN 120732855 A CN120732855 A CN 120732855A CN 202511190792 A CN202511190792 A CN 202511190792A CN 120732855 A CN120732855 A CN 120732855A
Authority
CN
China
Prior art keywords
compound
liver
day
administered
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511190792.8A
Other languages
English (en)
Chinese (zh)
Inventor
肯尼思·宋
休伯特·陈
布兰迪·瓦格纳
尼古拉斯·D·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN120732855A publication Critical patent/CN120732855A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202511190792.8A 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂 Pending CN120732855A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062991292P 2020-03-18 2020-03-18
US62/991292 2020-03-18
US202063069667P 2020-08-24 2020-08-24
US63/069667 2020-08-24
US202163140735P 2021-01-22 2021-01-22
US63/140735 2021-01-22
PCT/US2021/022786 WO2021188688A1 (en) 2020-03-18 2021-03-17 Farnesoid x receptor agonists for the treatment of disease
CN202180036461.2A CN115666559A (zh) 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180036461.2A Division CN115666559A (zh) 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂

Publications (1)

Publication Number Publication Date
CN120732855A true CN120732855A (zh) 2025-10-03

Family

ID=77771857

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202511190792.8A Pending CN120732855A (zh) 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂
CN202180036461.2A Pending CN115666559A (zh) 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂
CN202511190799.XA Pending CN120732856A (zh) 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂
CN202511190786.2A Pending CN120732854A (zh) 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202180036461.2A Pending CN115666559A (zh) 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂
CN202511190799.XA Pending CN120732856A (zh) 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂
CN202511190786.2A Pending CN120732854A (zh) 2020-03-18 2021-03-17 用于治疗疾病的法尼醇x受体激动剂

Country Status (12)

Country Link
US (1) US20230131804A1 (cg-RX-API-DMAC7.html)
EP (1) EP4121048A4 (cg-RX-API-DMAC7.html)
JP (1) JP7851856B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220154801A (cg-RX-API-DMAC7.html)
CN (4) CN120732855A (cg-RX-API-DMAC7.html)
AU (1) AU2021240001A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018651A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172205A1 (cg-RX-API-DMAC7.html)
IL (1) IL296539A (cg-RX-API-DMAC7.html)
MX (1) MX2022011579A (cg-RX-API-DMAC7.html)
TW (1) TWI895384B (cg-RX-API-DMAC7.html)
WO (1) WO2021188688A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852748B1 (en) 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof
CN120227340A (zh) 2020-03-18 2025-07-01 伊莱利利公司 法尼醇x受体激动剂的制剂
JP7664278B2 (ja) * 2020-03-18 2025-04-17 オルガノボ,インク. ファルネソイドx受容体アゴニストの結晶質形態
CN117018000B (zh) * 2023-08-29 2025-01-28 东莞市东南部中心医院(东莞市东南部中医医疗服务中心) 4-胆甾烯-3-酮在制备预防或治疗炎症性肠病药物中的应用
WO2026149323A1 (en) * 2025-01-07 2026-07-16 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of using mitochondrial uncouplers and glp-1 receptor agonists
CN120837611B (zh) * 2025-09-22 2025-12-16 吉林大学 一种经鼻给药的司美格鲁肽制剂及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2016233579A1 (en) * 2015-03-13 2017-10-12 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
WO2017049176A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3350165B1 (en) 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
AU2018236275B2 (en) * 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
DK3596053T3 (da) * 2017-03-15 2023-09-25 Organovo Inc Farnesoid-x-receptoragonister og anvendelser deraf
EP3852748B1 (en) * 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof

Also Published As

Publication number Publication date
IL296539A (en) 2022-11-01
CN120732854A (zh) 2025-10-03
EP4121048A4 (en) 2024-06-12
US20230131804A1 (en) 2023-04-27
EP4121048A1 (en) 2023-01-25
JP7851856B2 (ja) 2026-04-27
CA3172205A1 (en) 2021-09-23
JP2023518397A (ja) 2023-05-01
KR20220154801A (ko) 2022-11-22
BR112022018651A2 (pt) 2022-11-29
AU2021240001A1 (en) 2022-10-13
CN115666559A (zh) 2023-01-31
WO2021188688A1 (en) 2021-09-23
TWI895384B (zh) 2025-09-01
CN120732856A (zh) 2025-10-03
TW202143961A (zh) 2021-12-01
MX2022011579A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
US20220323414A1 (en) Farnesoid x receptor agonists for the treatment of disease
TWI895384B (zh) 用於治療疾病之法尼醇x受體促效劑
Hu et al. Pipeline of new drug treatment for non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease
JP7369033B2 (ja) 線維症の治療
US20120071451A1 (en) Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
KR102338085B1 (ko) 담즙울체성 질환의 치료 방법
JP2017528431A (ja) 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム
KR20210092754A (ko) Nafld 및 nash의 병용 치료
CN110876751B (zh) 曲美替尼在制备预防和/或治疗非酒精性肝炎和/或非酒精性脂肪性肝病中的应用
TW202114672A (zh) 使用fxr促效劑的肝臟疾病之組合治療
Ezhilarasan Mechanism of semaglutide in MASLD treatment: where is the master key?
US20190175619A1 (en) Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
TW202143958A (zh) 用於治療疾病之法尼醇x(farnesoid x)受體促效劑
HK40131843A (en) Farnesoid x receptor agonists for the treatment of diseases
HK40131844A (en) Farnesoid x receptor agonists for the treatment of disease
CN114401745A (zh) 包含fxr激动剂的治疗
US20250332176A1 (en) Treatment for fibrosis and inhibition of fibrosis
KR102027750B1 (ko) 당 배출용 조성물
HK1237676A1 (en) Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
JP2019537607A (ja) 非アルコール性脂肪性肝疾患の患者における線維化の抑制

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40131843

Country of ref document: HK